Want to claim a name? FDA needs your input on locking down brand monikers

Justin Heifetz

Advertising experts have a few tricks up their sleeves when concocting a drug's proprietary –like Zytiga, Xtandi and Xeljanz–that might thrust the product to success. Now, the FDA is looking for ideas about allowing drugmakers to reserve these names in advance–with a few rules.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS